‘Triple-G’ weight loss drug update: Even on the lowest dose, trial patients lost 12.7% of their weight - New York Post

As reported by New York Post

The drug, the first of its kind to target three metabolic receptors (GLP-1, GIP, and glucagon), is nearing the end of clinical trials and is expected to be submitted to the FDA for approval early n…

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on New York Post ↗

Market Samachar is a news aggregator. This article was originally published by New York Post. Tap the button above to read the full story on their site.

INDIAN Fed officials give hints on rate decision as markets cut October rate hike odds Markets-Economic Times
INDIAN Why US stocks are rising: Nasdaq hits record after weaker jobs data cools rate-hike bets; Nike shares drop on forecast Markets-Economic Times
INDIAN Sleepless on Wall Street: All-night stock exchanges coming soon Markets-Economic Times
INDIAN Bets on US Federal Reserve rate hike in October fall as job market cools Markets-Economic Times
INDIAN Nike's struggles test investor confidence in CEO Hill's turnaround effort Markets-Economic Times
INDIAN Nasdaq climbs to record after softer jobs data cools rate-hike expectations mint - markets
INDIAN Sumeet Bagadia's top 3 stocks to buy: HDFC Life, Cummins India, CG Power | Target, stoploss, Nifty, Bank Nifty outlook mint - markets
INDIAN Dividend jackpot shares: Coal India, Wipro, ITC, BPCL or ONGC? Which large cap stock has the highest yield? Data details mint - markets

‘Triple-G’ weight loss drug update: Even on the lowest dose, trial patients lost 12.7% of their weight - New York Post

More from Market Samachar